论文部分内容阅读
目的探讨盐酸埃克替尼和多西他赛在晚期非小细胞肺癌序贯治疗中的临床效果。方法 43例晚期非小细胞肺癌患者相关资料进行分析,将患者随机分为两组,对照组20例采用多西他赛治疗,实验组23例采用盐酸埃克替尼治疗,比较两组治疗效果。结果实验组疾病控制率87%高于对照组的55%;实验组无进展生存期为(5.08±0.21)个月,长于对照组的(4.94±0.23);实验组不良反应发生率为26%,低于对照组的50%;两组比较,差异均具有统计学意义(P<0.05)。结论晚期非小细胞肺癌患者采用盐酸埃克替尼治疗疗效确切,能够延长患者无进展生存期,且药物副作用较少,值得推广使用。
Objective To investigate the clinical efficacy of icotinol and docetaxel in the sequential treatment of advanced non-small cell lung cancer. Methods 43 patients with advanced non-small cell lung cancer were analyzed. The patients were randomly divided into two groups. The control group was treated with docetaxel, and the experimental group was treated with icotinib hydrochloride. The treatment effect was compared between the two groups . Results The disease control rate in the experimental group was 87% higher than that in the control group (55%). The progression-free survival rate in the experimental group was (5.08 ± 0.21) months longer than that in the control group (4.94 ± 0.23). The adverse reaction rate in the experimental group was 26% , Which was lower than 50% of the control group. The differences between the two groups were statistically significant (P <0.05). Conclusion The treatment of patients with advanced non-small cell lung cancer with icotinib is effective and can prolong the progression-free survival of patients with fewer side effects. It is worthy of promotion.